Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.55 |
| ▸ | CHRM3 | P20309 | 9/20 | 0.54 |
| ▸ | CHRM2 | P08172 | 6/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.53 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27620093 | 0.98 | CHRM3 (0.56) | CYP19A1CHRM3CHRM2LMNACYP2D6 | |
| SCHEMBL31147060 | 0.86 | CYP19A1 (0.56) | CYP19A1CHRM3CHRM2LMNACYP2D6 | |
| SCHEMBL28553376 | 0.82 | CYP19A1 (0.51) | CYP19A1CHRM3CHRM2LMNACYP2D6 | |
| Bromide SCHEMBL11465570 | 0.80 | CHRM3 (0.55) | CHRM3CHRM2LMNACYP2D6CYP2C19 | |
| SCHEMBL14753782 | 0.80 | CYP3A4 (0.70) | CHRM3CHRM2CYP2D6CYP2C19KCNH2 | |
| SCHEMBL14753777 | 0.80 | CYP3A4 (0.70) | CHRM3CHRM2CYP2D6CYP2C19KCNH2 | |
| SCHEMBL31147066 | 0.79 | CYP19A1 (0.52) | CYP19A1CHRM3CHRM2LMNACYP2D6 | |
| SCHEMBL23325147 | 0.79 | ALDH1A1 (0.70) | CHRM3CHRM2CYP2D6KCNH2 | |
| Hydrochloric Acid SCHEMBL11465418 | 0.78 | CHRM3 (0.54) | CHRM3CHRM2LMNACYP2D6CYP2C19 | |
| SCHEMBL6347301 | 0.77 | CHRM3 (0.48) | CYP19A1CHRM3CHRM2LMNACYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023214426-A1 | PROCESS FOR THE PREPARATION OF R-OXYBUTYNIN HYDROCHLORIDE | HARMAN FINOCHEM LIMITED (IN) | 2023-11-09 | — | — | WO | disclosed |
| US-8513455-B2 | — | — | 2013-08-20 | — | — | US | disclosed |
| US-20110087042-A1 | CRYSTALLINE OXYBUTYNIN AND PROCESS FOR PREPARING THE SAME | MATRIX LABORATORIES LIMITED (IN) | 2011-04-14 | — | — | US | disclosed |
| WO-2009122429-A2 | CRYSTALLINE OXYBUTYNIN AND PROCESS FOR PREPARING THE SAME | MATRIX LABORATORIES LIMITED (IN) | 2009-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110087042-A1 | CRYSTALLINE OXYBUTYNIN AND PROCESS FOR PREPARING THE SAME | HBB, CRYAB, OSBP | CYP19A1 1511/4885CHRM3 179/4885CHRM2 643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.